Lupus News and Research

Latest Lupus News and Research

BU professor to study incidence of hypertension, diabetes and asthma in African American women

Patricia F. Coogan, ScD, an associate professor of epidemiology at Boston University's Slone Epidemiology Center (SEC), recently was awarded funding for two grants from the National Institutes of Health.

21 Dec 2011

ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS

The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.

19 Dec 2011

LFA praises Congress for vital lupus funding in Fiscal Year 2012 Omnibus Appropriations Bill

The Lupus Foundation of America (LFA) applauds Congress for including vital lupus funding in the Fiscal Year 2012 Omnibus Appropriations Bill, which passed today, Saturday, December 17.

19 Dec 2011

Scientists discover how intestinal tract influences B cells to prevent infection

Researchers at the University of Toronto have found an explanation for how the intestinal tract influences a key component of the immune system to prevent infection, offering a potential clue to the cause of autoimmune disorders like rheumatoid arthritis and multiple sclerosis.

13 Dec 2011

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the receipt of verbal notification from the Food and Drug Administration that the company may proceed with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis based on a trial protocol submitted by the company in October 2011.

2 Dec 2011

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.

1 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

Counterparts of memory cells ward off microbial foes

The immune system possesses a type of cell that can be activated by tissues within the body to remind the immune system not to attack our own molecules, cells and organs, UCSF researchers have discovered.

29 Nov 2011

Most autoimmune diseases associated with increased risk of blood clots on the lung

Autoimmune diseases, in which the immune system attacks the body, are fairly common. Thyroid diseases, type 1 diabetes, rheumatoid arthritis, psoriasis and inflammatory bowel disease are some examples. Autoimmune diseases are associated with increased inflammation in the tissue, which in some cases is linked to an increased propensity to develop clots in the veins.

29 Nov 2011

Scientists search for main culprit behind Sj-gren's syndrome

Researchers want to find the main culprit behind the dry, irritated eyes, mouth, throat, skin, nose and more afflicting 1-3 percent of the population.

22 Nov 2011

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

An anti-malaria drug used for more than 60 years is now being studied for use in breast cancer patients whose disease has not responded to traditional chemotherapy treatment.

18 Nov 2011

Mycophenolate mofetil superior to azathioprine for lupus nephritis

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.

17 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Native Americans, Hispanics and Asians have higher incidence of lupus

In an abstract being presented today during the American College of Rheumatology Annual Scientific Meeting in Chicago, Dr. S. Sam Lim of Emory University School of Medicine will present data showing that black women have a significantly higher incidence of systemic lupus erythematosus than most reports in the scientific literature.

9 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

Patients with lupus nephritis ESRD choose hemodialysis as initial therapy

Newly published research shows that more patients with end-stage renal disease (ESRD) caused by lupus nephritis choose hemodialysis as their initial kidney replacement therapy over peritoneal dialysis and preemptive kidney transplantation.

7 Nov 2011

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Abbott today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up to 10 years in patients with long-standing moderate to severe RA, respectively.

7 Nov 2011

Lupus patients with low socioeconomic status miss scheduled doctors' appointments

The first step towards successful medical care is to see a physician, but for some patients this isn't as simple or easy as it may sound.

7 Nov 2011

Lupus News and Research

Latest Lupus News and Research

BU professor to study incidence of hypertension, diabetes and asthma in African American women

ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS

LFA praises Congress for vital lupus funding in Fiscal Year 2012 Omnibus Appropriations Bill

Scientists discover how intestinal tract influences B cells to prevent infection

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

Counterparts of memory cells ward off microbial foes

Most autoimmune diseases associated with increased risk of blood clots on the lung

Scientists search for main culprit behind Sj-gren's syndrome

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

Mycophenolate mofetil superior to azathioprine for lupus nephritis

Idera third quarter net loss increases to $5.5 million

Native Americans, Hispanics and Asians have higher incidence of lupus

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott announces results from HUMIRA Phase 3 study on axSpA

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

Patients with lupus nephritis ESRD choose hemodialysis as initial therapy

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Lupus patients with low socioeconomic status miss scheduled doctors' appointments

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Lupus News and Research

Latest Lupus News and Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in